December 3, 2021

Cortexyme Announces Agreement to Acquire Novosteo

‍SOUTH SAN FRANCISCO, Calif. – May 10,2022 – Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury.